Loading clinical trials...
Loading clinical trials...
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1) to alvimopan or placebo. The primary objective of...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Collaborators
NCT07545772 · Irritable Bowel Syndrome, Constipation
NCT07213986 · Neurogenic Bowel Dysfunction, Spinal Cord Injury
NCT05588323 · Opioid-Induced Constipation (OIC)
NCT07511244 · Bladder and Bowel Dysfunction, SCI - Spinal Cord Injury
NCT07215351 · Constipation, Bloating
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions